BMY Stock: Price, Earnings History and SEC Filings
Bristol-Myers Squibb Company (BMY) last traded at $62.48, up 1.78% on the latest session and up 0.1% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $1.35 against an analyst estimate of $1.21, a beat of 11.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BMY earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $1.35 | $1.21 | +11.57% |
| Jun 2026 | Jul 30, 2026 | $2.04 | $1.59 | +28.30% |
| Mar 2026 | Apr 30, 2026 | $1.58 | $1.44 | +9.72% |
| Dec 2025 | Feb 5, 2026 | $1.26 | $1.15 | +9.57% |
BMY beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How BMY reacts to earnings
Across its last 8 earnings releases, BMY moved 3.7% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | +1.35% |
| 2026-07-30 | Before open | +2.79% |
| 2026-04-30 | Before open | +5.21% |
| 2026-02-05 | Before open | +3.30% |
| 2025-10-30 | Before open | +7.09% |
| 2025-07-31 | Before open | -5.81% |
| 2025-04-24 | Before open | +0.33% |
| 2025-02-06 | Before open | -3.84% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BMY financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $48.2B | $7.1B | $12.8B | 14.6% | $3.46 |
| 2024 | $48.3B | -$8.9B | $13.9B | -18.5% | $-4.41 |
| 2023 | $45.0B | $8.0B | $12.7B | 17.8% | $3.86 |
| 2022 | $46.2B | $6.3B | $11.9B | 13.7% | $2.95 |
| 2021 | $46.4B | $7.0B | $15.2B | 15.1% | $3.12 |
| 2020 | $42.5B | -$9.0B | $13.3B | -21.2% | $-3.99 |
| 2019 | $26.1B | $3.4B | $7.4B | 13.2% | $2.01 |
| 2018 | $22.6B | $4.9B | $6.1B | 21.8% | $3.01 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BMY
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 8, 2026Shareholder vote
- 10-Q · Apr 30, 2026
- 8-K · Apr 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Mar 25, 2026
- 10-K · Feb 11, 2026
- 8-K · Feb 5, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
BMY insiders filed 11 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BMY news
- Bristol Myers Squibb stock heads into pipeline-focused weekNov 1, 2026 · ad-hoc-news.de
- What Bristol Myers Squibb Stock's Earnings Beat Means For ShareholdersOct 31, 2026 · finance.yahoo.com
- Bristol Myers Squibb (BMY) Reports Positive Phase 2 Pumitamig Lung Cancer DataOct 31, 2026 · finance.yahoo.com
- MarketBeat Week in Review – 10/26 - 10/30Oct 31, 2026 · marketbeat.com
- AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling StockOct 30, 2026 · finance.yahoo.com
- Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)Oct 30, 2026 · seekingalpha.com
- BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline ProgressOct 30, 2026 · finance.yahoo.com
- Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?Oct 30, 2026 · 247wallst.com
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.